HC Wainwright Increases Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $22.00

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) had its target price boosted by investment analysts at HC Wainwright from $21.00 to $22.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 86.13% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Wedbush restated an “outperform” rating and issued a $18.00 price target (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Canaccord Genuity Group lifted their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, BMO Capital Markets increased their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.57.

Read Our Latest Research Report on Y-mAbs Therapeutics

Y-mAbs Therapeutics Stock Down 3.0 %

NASDAQ YMAB opened at $11.82 on Monday. The firm’s fifty day moving average price is $15.29 and its two-hundred day moving average price is $11.39. Y-mAbs Therapeutics has a 1 year low of $4.60 and a 1 year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The business had revenue of $23.36 million during the quarter, compared to the consensus estimate of $21.72 million. On average, analysts anticipate that Y-mAbs Therapeutics will post -0.46 earnings per share for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, SVP Vignesh Rajah sold 1,711 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares of the company’s stock, valued at $560,185.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently modified their holdings of YMAB. Acadian Asset Management LLC lifted its position in Y-mAbs Therapeutics by 24.0% during the third quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock worth $4,420,000 after purchasing an additional 157,173 shares during the period. GSA Capital Partners LLP increased its stake in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after acquiring an additional 92,765 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter valued at approximately $562,000. Trexquant Investment LP lifted its stake in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after purchasing an additional 61,785 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after purchasing an additional 59,201 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Further Reading

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.